Zenafil – the “Little Blue Spray” erectile dysfunction treatment. Works in as little as 3 – 5 minutes with a reduction in possible side effects. Why Zenafil …
Video Rating: 4 / 5
Albuquerque, NM (PRWEB) August 13, 2014
A leading national provider of medical care for mens sexual health and enhancement, NuMale Medical Center, announced the opening of its newest facility today in Albuquerque. This is the companys sixth center, and its first in New Mexico. NuMales Albuquerque facility will continue the companys commitment to employing a safe, science-based approach to treat issues facing men of all ages.
Headed by Chief Medical Officer and founder Dr. Christopher Asandra, M.D., NuMale takes an integrated approach to male sexual health and overall wellness. At NuMale, every patient receives a comprehensive, confidential medical evaluation and consultation on their first visit. This helps the expert doctors at NuMale identify the most appropriate, individually tailored approach to address the patients needs.
NuMale offers a wide array of therapeutic services for men, including:
Dallas, Texas (PRWEB) September 12, 2014
Laparoscopy is a minimally invasive surgical technique performed with the assistance of a video camera and several thin instruments. The devices used to perform laparoscopic surgery are called laparoscopic devices. The benefits of laparoscopic procedures are less postoperative discomfort, quicker recovery, shorter hospital stays, and small external and internal scars. Laparoscopy is performed for surgeries related to the pancreas, liver, colon, and bile duct.
Analysts forecast the Global Laparoscopic Device market to grow at a CAGR of 9.14 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Laparoscopic Device market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of the following laparoscopic devices:
Bury, Greater Manchester (PRWEB UK) 16 September 2014
Sexual Health Week began yesterday, running until the 21 September, and this year the focus is on emergency contraception.
The week-long campaign is one that has been proudly supported by Medical Specialists
Albany, New York (PRWEB) September 24, 2014
The global erectile dysfunction drugs market was worth $ 4.3 billion in 2012. It is expected to decline at an aggregate rate of 4.5% between 2013 and 2019, which means the market will be valued at $ 3.4 billion in 2019.
All facts and figures have be provided through a research report titled Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 2019, published by Transparency Market Research.
To browse through the research report, or to view the ToC, please visit: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html
The report showed that Viagra (sildenafil citrate) by Pfizer held 45% of the global erectile dysfunction drugs market in 2012. Its majority hold over the market is predicted to decline after patent exclusivity rights expire in 2013 in Europe and other countries. Cialis (tadalafil) held the second-largest market share with $ 1.9 billion in 2012. Its patent exclusivity will reportedly expire in 2017, supplementing the decline of the erectile dysfunction drugs market by 2019. The same is to be expected from Levitra/Staxyn (Vardenafil) by Bayer, whose patent exclusivity is set to expire in 2018. The report explains that once the patents expire, the market will be flooded with competitive generic drugs with similar chemical compositions, reducing the revenue generated by the major players in the market.
Factors that might improve the growth of the erectile dysfunction drugs market are the approval of the new promising drugs Zydena (udenafil) and Stendra/Spedra (avanafil) in mid 2014.
The report categorized the global erectile dysfunction market according to the product brands or pipeline analysis. By products, the report investigates Viagra, Cialis, Levitra/Staxyn, MUSE, Zydena, Mvix, and Helleva. By pipeline analysis, the report identifies Vitaros, Uprima, Gene therapy, Melanocortin Activators, and Topiglan.
For further inquiries, ask here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550
By geography, the research report identifies the regions of North America, Europe, Asia-Pacific, and Rest of the World. The North American region dominated the global erectile dysfunction drug market in revenue created. It is expected to maintain its dominance throughout the forecast period.
The key players explained in the report are Pfizer, GlaxoSmithKline, Bayer, Dong-A Pharmaceutical Corporation Limited, Eli Lilly And Company, Cristalia Produtos Quimicos Farmaceuticos Ltda., Vivus Incorporated, S.K. Chemicals Corporation Limited, Meda Pharmaceuticals, and Apricus Biosciences, Incorporated.
Erectile dysfunction is a male inability to generate and/or maintain penile erection, for the sake of a fully successful sexual intercourse. It primarily affects men above the age of 40. Typical causes of erectile dysfunction are diabetes and hypertension, along with a host of common habits attributed to a sedentary lifestyle, obesity, excessive consumption of alcohol, smoking, use of recreational drugs, and use of anti-depressants.
90 Sate Street, Suite 700
Albany, NY 12207
USA/Canada Toll Free: 866-552-3453
Erectile dysfunction treatment is possible with natural remedies. See 3 easy natural remedies to cure erectile dysfunction. Visit http://www.ekunji.com/healt…
Congress wants to cut Medicare coverage of a legit medical device: penis pumps
Elimination of the government subsidy for the erectile function devices is tied up in a House bill with pretty significant bipartisan support to create tax-advantaged bank accounts for people with disabilities. And no one's really taking a public stand …
Read more on Washington Post (blog)
ED Protocol (Erectile Dysfunction Protocol) Review – DOES IT REALLY WORK?
Caused by low testosterone levels, erectile dysfunction is an issue which is being faced by a lot of men in the world these days. While there are many ways to treat this condition, no specific treatment method guarantees accurate and swift results …
Read more on DigitalJournal.com
Sexual Function, Mental Health Linked in Rheumatic Disease
FRIDAY, Nov. 7, 2014 (HealthDay News) — The presence of anxiety and depression in people with rheumatic diseases may be an independent predictor of sexual dysfunction, according to a study published in the November issue of the Journal of Sexual …
Read more on HCPLive
Port Washington, New York (PRWEB) September 15, 2014
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications reports that a recent study found that use of Viagra (sildenafil citrate), which is also sold under the brand Revatio, is tied to increased risks for melanoma. The study appears in the April 7, 2014 issue of JAMA International Medicine.
The research, a prospective cohort study, was conducted by Wen-Qing Li, PhD, from the Department of Dermatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, and colleagues. Study participants from the Health Professionals’ Follow-up Study (HPFS) from 2000 and 2010 were involved; 25,848 men were participants, according to JAMA International Medicine. The study followed prior research that revealed that phosphodiesterase (PDE) 5A (PDE5A) inhibitors, which include sildenafil (Viagra), may increase the synthesis of melanin, which may, in turn, increase the development of melanoma. In fact, according to the study, prior published research revealed an association with sildenafil (Viagra) use and other PDE5A inhibitors to increased melanoma cell invasion, especially in people who carry a mutation in the BRAF gene. The current review did not include a review of other PDE5A inhibitors, such as Eli Lillys Cialis (tadalafil) and GlaxoSmithKlines Levitra (vardenafil) because these drugs were not approved when the cohort research was initiated.
HPFS study participants were questioned in a 2000 survey if they had been, or were ever, treated for erectile dysfunction (ED). Of the participants, 13785.3 percentindicated that they had taken sildenafil (Viagra) in the prior three months; 1618or 6.3 percentof the participants reported ever having taken the ED drug. The participants reported diagnoses of melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) in the surveys since 1986. In follow-up from 2000 through 2010, researchers discovered 142 cases of melanoma, which is the deadliest form of skin cancer, JAMA indicated. Men who had recently used sildenafil (Viagra) experienced a significantly increased likelihood of being diagnosed with invasive melanoma when compared to non-users and men who had ever used the ED drug experienced an increased risk for melanoma, as well.
Although other PDE5A inhibitors were not studied, the researchers noted in JAMA that, “The observed association between sildenafil use and melanoma might be partly attributed to the later use of vardenafil and tadalafil among recent sildenafil users. A longer clearance time of other PDE5A inhibitors could have augmented the observed HR for sildenafil.” The researchers added that, while the results are not sufficient to change current use recommendations, the data provide epidemiological evidence on possible skin adverse effects of PDE5A inhibitors and support continued investigation of this relationship.”
Ryan Sullivan, M.D., of Massachusetts General Hospital in Boston told MedPage Today that, Sildenafil may promote tumor growth, at least in tumor cells and noted that, should a Viagra melanoma cause and effect be confirmed in future research, the effect on melanoma risk will likely apply to all drugs in the PDE5A-inhibitor class, including Cialis and Levitra.
The U.S. Food and Drug Administration (FDA) approved Viagra in 1988 for the treatment of ED in men. Other known Viagra side effects include, heartburn, nausea, and headaches. Men who suffer from angina or very high blood pressure are advised against taking the drug. Since approval, the FDA has issued Press Announcements regarding Viagra and the drugs ties to reports of sudden hearing loss, as well as of non-arteritic ischemic optic neuropathy (NAION), a type of eye disorder that may lead to permanent vision loss when blood flow is blocked to the optic nerve. Viagra has also long been associated with short-term color changes in vision that cause objects to appear green or blue. The FDA announced labeling changes in 2007 for PDE5A medications to ensure the hearing problem risk was placed more prominently on the labeling following research linking these drugs to sudden hearing loss. In 2005, warnings about vision loss were added to the labels.
Viagra has already been tied to a number of serious adverse health effects, said Gary Falkowitz, Managing Attorney at Parker Waichman LLP. We hope that additional research will lead to more stringent labeling on this class of drugs and that, awareness of these potential reactions will lead to stronger screening and follow-up on patients taking these drugs, Falkowitz added.
[Parker Waichman LLP continues to offer free legal consultations to victims who have suffered adverse health effects after using medications, such as Viagra. If you or a loved one experienced an adverse reaction after taking Viagra or other PDEA5 inhibitors, please contact the firm by visiting yourlawyer.com and the Viagra Melanoma page. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636) or 1-800-YOUR LAWYER (1-800-968-7529).
Penis Problems: Are You at Risk of Erectile Dysfunction?
(HealthNewsDigest.com) – The fear of developing erectile dysfunction is very real for many men. However, not only are there a number of effective ways to treat the condition, but there are also many preventative measures you can take to reduce the …
Read more on HealthNewsDigest.com
Apricus Biosciences Announces the Launch of Its Topical Treatment for Erectile …
The Company's lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and will be commercialized by Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International …
Read more on GlobeNewswire (press release)
New Grant Enables Humanetics Corporation to Evaluate Potential Treatment for …
… Corporation (Humanetics) has been awarded a grant from the National Cancer Institute (NCI) to evaluate their proprietary radioprotectant compound, BIO 300, as a potential treatment for erectile dysfunction (ED) following prostate cancer radiotherapy.
Read more on Business Wire (press release)
This is Part 2 of a 3 part series examining the use of Penile Vibration Therapy for penile rehabilitation following prostate cancer treatment. In this part o…